Rawcliffe Adrian 4
4 · Adaptimmune Therapeutics PLC · Filed Feb 20, 2025
Insider Transaction Report
Form 4
Rawcliffe Adrian
DirectorChief Executive Officer
Transactions
- Award
Option to purchase Ordinary Shares
2025-02-20+5,143,248→ 5,143,248 totalExercise: $0.10Exp: 2035-02-20→ Ordinary Shares (5,143,248 underlying) - Award
Option to purchase Ordinary Shares
2025-02-20+3,428,832→ 3,428,832 totalExercise: $0.00→ Ordinary Shares (3,428,832 underlying)
Footnotes (5)
- [F1]The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F2]Exercisable as to 1,285,812 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 107,148 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 107,256 Ordinary Shares on February 20, 2029.
- [F3]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F4]Exercisable as to 857,208 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 857,208 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029.
- [F5]The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.